Stattin P, Karlberg L, Damber J E
Department of Urology & Andrology, Umeå University, Sweden.
Scand J Urol Nephrol. 1996 Apr;30(2):109-13. doi: 10.3109/00365599609180899.
The long-term outcome of 106 patients treated for hydrocele with the sclerosing agent sodium tetradecyl sulphate was examined. In a questionnaire distributed at a mean time of 40 months after therapy 83/86 (96%) of the eligible patients responded and 95% of them were satisfied with the treatment and its long term results. The treatment associated pain was evaluated on a visual analogue scale (0-10) the mean pain score was found to be 1.8 and the mean duration of the pain 2.4 days. When all hydroceles were considered the overall success rate was 88%. Side-effects were minor apart from two patients (1.9%) with diabetes mellitus who had an intense inflammatory reaction necessitating orchidectomy after sclerotherapy.
对106例接受硬化剂十四烷基硫酸钠治疗鞘膜积液的患者的长期预后进行了研究。在治疗后平均40个月发放的一份问卷中，86名符合条件的患者中有83名（96%）做出了回应，其中95%的患者对治疗及其长期效果感到满意。采用视觉模拟评分法（0-10分）对治疗相关疼痛进行评估，发现平均疼痛评分为1.8分，疼痛平均持续时间为2.4天。当将所有鞘膜积液病例纳入考虑时，总体成功率为88%。除两名糖尿病患者（1.9%）在硬化治疗后出现强烈炎症反应而需要进行睾丸切除外，副作用较小。
